Vasomedical Announces Strong Revenue Growth for the Three Months Ended March 31, 2012

Advanced Heart Disease Patient Regains Lost Energy, Attends 50-Year Class Reunion After Receiving EECP® Therapy at Heart House in Washington Township

Vasomedical Successfully Exhibited at the 61st Annual Scientific Sessions of the American College of Cardiology

Vasomedical Announces Record Operating Income of $5.2 Million and 169% Increase in Revenue for the Seven Months Ended December 31, 2011

Florida Cardiologist Tells Angina Patients, “Don’t Give Up Hope: Non-Invasive EECP® Therapy Can Relieve Chest Pain when Stents and Bypasses Do Not”

More >>

November 25, 2011

Editorial on EECP® Therapy by Dr. Gregory Barsness of Mayo Clinic Appears in the Inaugural Edition of ONE HEART Magazine

WESTBURY, N.Y. November 25, 2011 –An editorial on EECP® therapy by Dr. Gregory Barsness, Division of Cardiovascular Disease and Internal Medicine at Mayo Clinic, was published last week in the first edition of One Heart magazine, a Global Alliance project of Heartbeat International, and has ben distributed to cardiologists, healthcare managers and government services throughout the USA and some foreign countries.

EECP® therapy is a noninvasive, outpatient treatment for patients who suffer from the symptoms and limitations of angina (including the angina equivalents of fatigue and shortness of breath) and congestive heart failure.  The editorial by Dr. Barsness, entitled “EECP Therapy: A Treatment for Heart Failure via Improvement in Endothelial Dysfunction,” discussed the benefits of EECP® therapy for the treatment of angina and heart failure and cited several studies on the mechanisms of action, particularly the endothelial function improvement and associated effects.  Dr. Barsness concluded that “Given the strong evidence that EECP is effective in improving endothelial dysfunction, the potential use and benefit of EECP in patients with heart failure is an attractive consideration.”

To read the editorial and see the advertisement for EECP® in the magazine go to www.oneheartmagazine.com and flip to page 34.

Heartbeat International, established in 1984, is a nonprofit organization, whose mission, “To save lives globally by providing cardiovascular implantable devices and follow care to the needy people of the world,” is a global alliance of individuals, corporations, non-governmental organizations, civic organizations, institutions and healthcare individuals. To learn more about Heartbeat International go to www.heartbeatsaveslives.com.

Vasomedical, Inc. is engaged in designing, manufacturing, marketing and supporting EECP® external counterpulsation systems based on the Company's proprietary technology. EECP® therapy is a non-invasive, outpatient therapy for the treatment of cardiovascular diseases and is currently indicated for use in cases of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. The Company provides hospitals, clinics and private practices with EECP® equipment, treatment guidance and a staff training and maintenance program designed to provide optimal patient outcomes. The Company also provides other noninvasive medical equipment including Holter monitors and ambulatory blood pressure monitors.

Vaso Diagnostics d/b/a VasoHealthcare, a wholly owned subsidiary of Vasomedical, Inc., is a professional sales representation organization offering vendors of medical devices an alternative third party sales channel. Through an agreement with GE Healthcare, it is currently engaged as an exclusive sales representative for certain GE Healthcare products.

Additional information is available on the Company's website at www.vasomedical.com.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.